Medicine and Dentistry
Patient
100%
Pancreas Cancer
66%
Inpatient
59%
Cytotoxic T-Cell
55%
Therapeutic Procedure
47%
Overall Survival
42%
B Cell
39%
T Cell
33%
Cytokine
33%
Serum
33%
Tumor Progression
33%
Gastrointestinal Stromal Tumor
33%
Urothelial Cancer
33%
T-Helper Cell
33%
Severe Acute Respiratory Syndrome Coronavirus 2
33%
Survival
33%
Enalapril Maleate
33%
Soft Tissue Sarcoma
25%
Tumor Infiltrating Lymphocyte
20%
Cells
20%
Flow Cytometry
20%
Sarcoma
16%
Immunocompetent Cell
16%
Myeloid Cell
16%
Receptor
15%
Treatment Response
14%
Pancreas Adenocarcinoma
13%
Lesion
13%
Immune Checkpoint Inhibitor
11%
COVID-19
11%
Marker
11%
Non Small Cell Lung Cancer
11%
Progressive Disease
10%
Association
10%
Diseases
9%
Immune Response
8%
Mutational Load
8%
Liposarcoma
8%
Ligand
8%
Nivolumab
8%
Cellular Immunity
6%
Phenotype
6%
Interleukin 18
6%
Interleukin 7
6%
Pembrolizumab
6%
Analysis
6%
Experience
6%
T Cell Subset
6%
Enzyme Linked Immunosorbent Assay
6%
Blood Plasma
6%
Immunology and Microbiology
Overall Survival
60%
Immunity
34%
Neutrophil Granulocyte
33%
Progression Free Survival
26%
Immunocompetent Cell
22%
Pembrolizumab
20%
Cell Population
16%
Cells
13%
Lymphocyte
13%
Flow
12%
Lung
11%
Association
10%
Monocyte
10%
Blood Sampling
9%
Immune Response
8%
Nivolumab
8%
Programmed Death-Ligand 1
6%
Survival
6%
Contrast
6%
Granulocyte
6%
Interleukin 18
6%
CD14
6%
Interleukin 7
6%
CD16
6%
Sample
6%
B Cell
5%
Differentiation
5%
Immunotherapy
5%
